Denali Therapeutics Inc (DNLI)

Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell

$14.06

Buy

$14.13

arrow-down$-0.32 (-2.22%)

Prices updated at 05 Jun 2025, 15:42 EDT
| Prices minimum 15 mins delay
|
Prices in USD
Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
NASDAQ
arrow-up0.45%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Biotechnology
Chairman
-
CEO
Dr. Ryan J. Watts, PhD
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
443
Head office
161 Oyster Point Boulevard
South San Francisco
United States
94080
mobile
+1 650 866-8547
letter
contact@dnli.com
computer
Company website

Key personnel

Owner name
chevron-l-regular
chevron-r-regular
Salary
Mr. Julian C. Baker
Independent Director
-
Mr. Jay T. Flatley
Independent Director
0.07m
Dr. Marc Tessier-Lavigne, PhD
Independent Director
0.06m
Mr. Peter S. Klein
Independent Director
0.07m
Dr. David P. Schenkein, M.D.
Independent Director
0.07m
Mr. Steven E. Krognes, M.B.A.
Director
0.05m
Dr. Ryan J. Watts, PhD
Director, President and Chief Executive Officer
0.69m
Dr. Alexander O. Schuth, M.D.
Secretary, Chief Financial Officer, Chief Operating Officer and Principal Accounting Officer
0.54m
Dr. Carole Ho, M.D.
Chief Medical Officer and Head of Development
0.54m
Ms. Jennifer E. Cook
Independent Director
0.06m
Ms. Nancy A. Thornberry
Independent Director
0.06m

Top 5 shareholders

Owner name
chevron-l-regular
chevron-r-regular
No. of shares
BlackRock, Inc.13,787,873
BlackRock Inc13,834,956
Baillie Gifford & Co Limited.12,090,040
Vanguard Group Inc11,799,757
Wellington Management Company LLP11,409,598

Director dealings

Date
chevron-l-regular
chevron-r-regular
Action
31 Dec 2024-
27 Dec 2024-
27 Dec 2024-
25 Nov 2024-
25 Nov 2024-
22 Nov 2024-
22 Nov 2024-
11 Nov 2024-
11 Nov 2024-
11 Nov 2024-
11 Nov 2024-
07 Nov 2024-
07 Nov 2024-
07 Nov 2024-
07 Nov 2024-
07 Nov 2024-
07 Nov 2024-
01 Nov 2024-
18 Oct 2024-
18 Oct 2024-
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.